Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21, 2017 – The European Commission (EC) has approved avelumab for the treatment of patients with metastatic Merkel cell carcinoma, according to Merck KGaA and Pfizer, the co-developers of the PD-L1 inhibitor. Avelumab is approved for this indication in all 28 EU member states, plus Iceland, Liechtenstein, and Norway. The FDA approved avelumab for Merkel cell carcinoma in March 2017. “The EC’s decision is significant for Bavencio and, more importantly … (leggi tutto)